News Details - novonordisk.com
5 days ago · About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient …
Novo Nordisk successfully completes phase 1b/2a trial with ...
1 day ago · About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient …
Novo Nordisk reports 22% weight loss with amycretin
15 hours ago · With amycretin, Novo Nordisk expects to improve on the efficacy of its blockbuster drug semaglutide, sold under the brand names Ozempic and Wegovy. Semaglutide is a …
Weight loss: Amycretin pill may be more effective than ...
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have …
Novo Nordisk next-gen shot shows 22% weight loss in early ...
4 days ago · In December, Novo said its CagriSema drug, which is far more advanced in development than amycretin, led to 22.7% weight loss after 68 weeks, below the 25% the …
Novo Nordisk shares jump on fresh trial results - Financial Times
4 days ago · People treated with amycretin lost up to 22 per cent of their body weight after 36 weeks. ... Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per …
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
3 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
- Some results have been removed